Datar Cancer Genetics (DCG), a global precision oncology company, today announced that its tissue-based comprehensive genomic ...

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new data demonstrating how comprehensive ...

A CGP assay that detects more than 700 cancer-relevant gene variants and molecular signatures, gives researchers new insights into tumour biology, expanding the potential for personalized cancer ...

We performed a single-institution, retrospective analysis of CGP utilization and treatment patterns in patients with localized PDAC who underwent curative-intent resection in the contemporary period ...

Explore MTAP deletion as a biomarker and how AI-powered genomic profiling improves detection and advances precision oncology ...

CGP identifies TP53 and SMAD4 mutations as negative prognostic markers, while PTEN mutations correlate with improved survival in CRC patients. Despite no significant survival advantage, CGP-guided ...

Illumina TruSight™ Oncology 500 v2 research assay is now available with built-in HRD biomarker detection, faster turnaround time, and lower tissue sample input Illumina's growing research and clinical ...

CNW/ - Pancreatic Cancer North America (PCNA) is launching a new national pilot that will provide pancreatic cancer patients ...

The UC Davis Comprehensive Cancer Center and the Department of Pathology and Laboratory Medicine have entered into a collaboration with Foundation Medicine, a leading molecular information company.

FDA Grants Breakthrough Device Designation to Foundation Medicine’s ctDNA Tracker The rise in popularity of genetic testing brings along a myriad of challenges ranging from concerns on data privacy to ...

A new national pilot program will provide pancreatic cancer patients across Canada with free access to advanced genomic ...